Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects

European Journal of Pharmacology

Volumn 578, Issue 1, 2008, Pages 76-86

  Ushiyama, Shigeru ^a   Yamada, Tomoko ^a   Murakami, Yukiko ^a   Kumakura, Sei ichiro ^a   Inoue, Shin ichi ^a   Suzuki, Keisuke ^a   Nakao, Akira ^a   Kawara, Akihiro ^a   Kimura, Tomio ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

COX 2 selective inhibitor; CS 706 2 (4 ethoxyphenyl) 4 methyl 1 (4 sulfamoylphenyl) 1H pyrrole ; Cyclooxygenase 2; Inflammation; Nociception; Non steroidal anti inflammatory drug

Indexed keywords

2 (4 ETHOXYPHENYL) 4 METHYL 1 (4 SULFAMOYLPHENYL) 1H PYRROLE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; CELECOXIB; CS 706; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NABUMETONE; NAPROXEN; PROSTAGLANDIN E2; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTHRITIS; ARTICLE; DRUG ABSORPTION; DRUG SELECTIVITY; ENZYME INHIBITION; FEMALE; FOOT EDEMA; IC 50; MALE; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; STOMACH MUCOSA; YEAST;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; INFLAMMATION; INHIBITORY CONCENTRATION 50; PAIN; PAIN MEASUREMENT; PYRROLES; RATS; RATS, INBRED LEW; RATS, WISTAR; SULFONAMIDES;

EID: 36549047970     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.08.034     Document Type: Article

References (36)

1. Bombardier C., et al., for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343 (2000) 1520-1528
2. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., Lines C., Riddell R., Morton D., Lanas A., Konstam M.A., and Baron J.A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352 (2005) 1092-1102
3. Brophy J.M. Celecoxib and cardiovascular risks. Expert. Opin. Drug Safety 4 (2005) 1005-1015
4. Esser R., Berry C., Du Z., Dawson J., Fox A., Fujimoto R.A., Haston W., Kimble E.F., Koehler J., Peppard J., Quadros E., Quintavalla J., Toscano K., Urban L., Duzer J., Zhang X., Zhou S., and Marshall P.J. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br. J. Pharmacol. 144 (2005) 538-550
5. Fletcher B.S., Kujubu D.A., Perrin D.M., and Herschman H.R. Structure of the mitogen-induced TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J. Biol. Chem. 267 (1992) 4338-4344
6. Food and Drug Administration. FDA Public Health Advisory: Safety of Vioxx (2004). http://www.fda.gov/cder/drug/infopage/vioxx/PHA_vioxx.htm Available: www.fda.gov/cder/drug/infopage/vioxx/PHA_vioxx.htm (accessed 2007 March 11)
7. Goldstein J.L., Eisen G.M., Agrawal N., Stenson W.F., Kent J.D., and Verburg K.M. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment Pharmacol. Ther. 20 (2004) 527-538
8. Graham D.J., Campen D., Hui R., Spence M., Cheetham C., Levy G., Shoor S., and Ray W.A. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 (2005) 475-481
9. Harris S.I., Stoltz R.R., LeComte D., and Hubbard R.C. Parecoxib sodium demonstrates gastrointestinal safety comparable to placebo in healthy subjects. J. Clin. Gastroenterol. 38 (2004) 575-580
10. Hitchens J.T., Goldstein S., Sambuca A., and Shemano I. Ulcerogenic effects of non-steroidal anti-inflammatory agents in rats. Pharmacologist 9 (1967) 242
11. Hla T., and Neilson K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 7384-7388
12. Jahn U., and Adrian R.W. Pharmakologische und toxikologische Prufung des neuen Antiphlogistcums Azapropazon. Arzneim.-Forsch./Drug Res. 19 (1969) 36-52
13. Jones S.C. Relative thromboembolic risks associated with COX-2 inhibitors. Ann. Pharmacother. 39 (2005) 1249-1259
14. Kuzuna S., and Kawai K. Evaluation of analgesic agents in rats with adjuvant arthritis. Chem. Pharm. Bull. 23 (1975) 1184-1191
15. Langman M.J.S., Weil J., Wainwright P., Lawson D.H., Rawlins M.D., Logan R.F.A., Murphy M., Vessey M.P., and Colin-Jones D.G. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343 (1994) 1075-1078 (published erratum appears in Lancet 343, 1302 (1994))
16. Malmstrom K., Daniels S., Kotey P., Seidenberg B.C., and Desjardins P.J. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo-and active-comparator-controlled clinical trial. Clin. Ther. 21 (1999) 1653-1663
17. Masferrer J.L., Zweifel B.S., Manning P.T., Hauser S.D., Leahy K.M., Smith W.G., Isakson P.C., and Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 3228-3232
18. Matsuda K., Tanaka Y., Ushiyama S., Ohnishi K., and Yamazaki M. Inhibition of prostaglandin synthesis by sodium 2-[4-(2-oxocyclopentylmethyl)phenyl]propionate dihydrate (CS-600), a new anti-inflammatory drug, and its active metabolite in vitro and in vivo. Biochem. Pharmacol. 33 (1984) 2473-2478
19. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296 (2006) 1633-1644
20. Moberly J.B., Harris S.I., Riff D.S., Dale J.C., Breese T., McLaughlin P., Lawson J., Wan Y., Xu J., and Truitt K.E. A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa. Dig. Dis. Sci. 52 (2007) 442-450
21. Moberly J.B., Xu J., Desjardins P.J., Daniels S., Bandy D.P., Lawson J.E., Link A.J., and Truitt K.E. A randomized, double blind, celecoxib- and placebo-controlled study of the effectiveness of CS 706 in acute postoperative dental pain. Clin. Ther. 29 (2007) 399-412
22. Nussmeier N.A., Whelton A.A., Brown M.T., Langford R.M., Hoeft A., Parlow J.L., Boyce S.W., and Verburg K.M. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 352 (2005) 1081-1091
23. 14C]CS-706, to the arterial elastin of rats. Drug Metab. Dispos. 34 (2006) 1417-1422
24. Oitate M., Hirota T., Takahashi M., Murai T., Miura S., Senoo A., Hosokawa T., Ohnishi T., and Ikeda T. Mechanism for covalent binding of rofecoxib to elastin of rat aorta. J. Pharmacol. Exp. Ther. 320 (2007) 1195-1203
25. Randall L.O., and Selitto J.J. A method for measurement of analgesic activity on inflamed tissue. Arch. Int. Pharmacodyn. Ther. 111 (1957) 409-419
26. Rohatagi S., Kastrissios H., Gao Y., Zhang N., Xu J., Moberly J., Wada R., Yoshihara K., Takahashi M., Truitt K., and Salazar D. Predictive population pharmacokinetic/pharmacodynamic model for a novel COX-2 inhibitor. J. Clin. Pharmacol. 47 (2007) 358-370
27. Schnitzer T.J., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., Ehrsam E., Gitton X., Krammer G., Mellein B., Matchaba P., Gimona A., Hawkey C.J., and TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet 364 (2004) 665-674
28. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W., Lee L., and Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 12013-12017
29. Shriver D.A., White C.B., Sandor A., and Rosenthale M.E. A profile of the rat gastrointestinal toxicity of drugs used to treat inflammatory diseases. Toxicol. Appl. Pharmacol. 32 (1975) 73-83
30. Singh G., Fort J.G., Goldstein J.L., Levy R.A., Hanrahan P.S., Bello A.E., Andrade-Ortega L., Wallemark C., Agrawal N.M., Eisen G.M., Stenson W.F., Triadafilopoulos G., and SUCCESS-I Investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am. J. Med. 119 (2006) 255-266
31. Solomon S.D., McMurray J.J.V., Pfeffer M.A., Wittes J., Fowler R., Finn P., Anderson W.F., Zauber A., Hawk E., Bertagnolli M., and Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352 (2005) 1071-1080
32. Solomon D.H., Avorn J., Stu{double acute}rmer T., Glynn R.J., Mogun H., and Schneeweiss S. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs. Arthritis Rheum. 54 (2006) 1378-1389
33. Takebe Y., Seiki M., Fujisawa J., Hoy P., Yokota K., Arai K., Yoshida M., and Arai N. SRα promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol. Cell Biol. 8 (1988) 466-472
34. Winder C.V., Lembke L.A., and Stephens M.D. Comparative bioassay of drugs in adjuvant-induced arthritis in rats. Flufenamic acid, mefenamic acid, and phenylbutazone. Arthritis Rheum. 12 (1969) 472-482
35. Winter C.A., and Flataker L. Reaction thresholds to pressure in edematous hindpaws of rats and responses to analgesic drugs. J. Pharmacol. Exp. Ther. 150 (1965) 165-171
36. Young J.M., Panah S., Satchawatcharaphong C., and Cheung P.S. Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm. Res. 45 (1996) 246-253